Ostatní
Návod 
HUTCHMED (China) Limited
HCM
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
2.6B
Obrat
1B
Zisk
0B
Aktiva
2B
Dluh
0B
ROE
38%
ROA
26%
PE
5
PS
4
Cena 1R
12-20
⌀ Cena
15.20
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
18-03-2026
Poslední dividenda
Profil
HUTCHMED (China) Limited objevuje, vyvíjí a komercializuje cílené terapie a imunoterapie rakoviny a imunologických chorob v Hongkongu a v mezinárodním měřítku. Působí v segmentech Onkologie/Imunologie a Další podniky. Společnost vyvíjí přípravek Savolitinib, inhibitor nemalobuněčného karcinomu plic (NSCLC), papilárního karcinomu a karcinomu ledvin, kolorektálního karcinomu (CRC) a karcinomu žaludku (GC); a Fruchintinib, inhibitor CRC, karcinomu prsu, GC, karcinomu endometria (EMC), NSCLC, hepatocelulárního karcinomu a gastrointestinálních a solidních nádorů. Vyvíjí se v něm také Surufatinib, inhibitor neuroendokrinních nádorů (NET), pankreatický NET, nepankreatický NET, rakovina žlučových cest, sarkom, neuroendokrinní novotvary, rakovina jícnu, malobuněčný karcinom plic, GC, karcinom štítné žlázy, EMC, NSCLC a solidní nádory; HMPL-523, inhibitor tyrosinkinázy sleziny pro hematologické nádory a některá chronická imunitní onemocnění; a HMPL-689 pro izoforma PI3Kd (delta fosfoinositidu 3'-kinázy). Dále se vyvíjí Tazemetostat, inhibitor EZH2 pro léčbu některých pacientů s epitelioidním sarkomem a folikulárním lymfomem; HMPL- 306, inhibitor hematologických malignit, gliomů a solidních nádorů; HMPL- 760, inhibitor Brutonovy tyrosinkinázy; HMPL- 453, inhibitor intrahepatického cholangiokarcinomu; HMPL- 295 pro solidní nádory; HMPL- 653 k léčbě metastatických solidních nádorů a tenosynoviálních tumorů obřích buněk; a inhibitory Epitinibu (HMPL- 813) a Theliatinibu (HMPL- 309). Má dohody o spolupráci se společnostmi AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd. a Epizyme, Inc. Společnost byla dříve známá jako Hutchison China MediTech Limited a v květnu 2021 změnila svůj název na HUTCHMED (China) Limited. Společnost byla založena v roce 2000 a sídlí ve městě Central v Hongkongu.
Sektor
Healthcare
Odvětví
Drug Manufacturers - Specialty & Generic
Počet zaměstnanců
1811
Založení
2016-03-16
Podobné společnosti
$ 6.60
- $ 0.05
$ 14.39
- $ 0.06
$ 30.79
+ $ 0.55
$ 45.02
- $ 1.00
$ 21.50
+ $ 0.11
$ 29.44
+ $ 0.49
$ 14.58
- $ 0.21
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 602.2 | 550.0 | 630.2 | 838.0 | 426.4 | 356.1 | 228.0 | 204.9 | 214.1 | 241.2 | 216.1 | 178.2 | 91.8 | 46.0 | 195.4 | 166.9 | 134.5 | |
| Cost of Revenues | 548.4 | 337.2 | 348.9 | 384.4 | 311.1 | 258.2 | 188.5 | 160.2 | 143.9 | 175.8 | 156.3 | 110.8 | 72.0 | 22.2 | 99.4 | 74.2 | 54.6 | |
| Gross Profit | 53.8 | 212.7 | 281.3 | 453.6 | 115.3 | 97.9 | 39.5 | 44.7 | 70.2 | 65.4 | 59.8 | 67.4 | 19.8 | 23.8 | 96.0 | 92.8 | 79.9 |
| Revenue | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 138.8 | 138.8 | 162.3 | 162.3 | 152.8 | 152.8 | 152.6 | 152.6 | 266.4 | 266.4 | |
| Cost of Revenues | 83.8 | 83.8 | 190.4 | 190.4 | 90.1 | 90.1 | 166.7 | 166.7 | 104.2 | 104.2 | |
| Gross Profit | 55.1 | 55.1 | -28.2 | -28.2 | 62.8 | 62.8 | -14.2 | -14.2 | 162.3 | 162.3 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 303.1 | 267.6 | 207.4 | 111.2 | 91.9 | 78.8 | 50.7 | 66.9 | 47.4 | 0.0 | 0.0 | 0.0 | 7.3 | 6.4 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 133.2 | 136.1 | 127.1 | 61.3 | 52.9 | 48.6 | 43.3 | 39.6 | 29.8 | 26.7 | 24.7 | 98.4 | 56.5 | 52.7 | |
| Depreciation & Amortization | 12.2 | 13.3 | 12.3 | 8.2 | 8.7 | 7.2 | 6.1 | 9.9 | 3.6 | 2.6 | 2.3 | 2.0 | 1.3 | 1.0 | 4.0 | 4.6 | 4.6 | |
| Total Operating Expenses | 73.5 | 267.4 | 321.9 | 436.2 | 523.0 | 426.2 | 236.1 | 189.8 | 161.0 | 118.8 | 106.6 | 77.2 | 26.9 | 23.1 | 95.4 | 87.2 | 82.5 | |
| Operating Income | -19.7 | -54.7 | -43.7 | 18.4 | -409.8 | -336.5 | -188.9 | -145.0 | -92.6 | -53.4 | -46.7 | -9.8 | 8.1 | 11.6 | 12.1 | 5.4 | -2.2 |
| Operating Income | TTM | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 79.2 | 79.2 | 72.3 | 72.3 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 32.5 | 32.5 | 34.1 | 34.1 | ||
| Depreciation & Amortization | 3.1 | 3.1 | 3.0 | 3.0 | 3.1 | 3.1 | 2.2 | 2.2 | 1.9 | 1.9 | ||
| Total Operating Expenses | 56.8 | 56.8 | -20.1 | -20.1 | 76.5 | 76.5 | 36.9 | 36.9 | 76.2 | 76.2 | ||
| Operating Income | -1.8 | -1.8 | -8.1 | -8.1 | -13.8 | -13.8 | -46.6 | -46.6 | 55.8 | 55.8 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 37.2 | 50.0 | 40.1 | 36.1 | 9.6 | 2.1 | 3.2 | 4.9 | 6.0 | 1.2 | 0.5 | 0.5 | 0.6 | 0.5 | 0.6 | 0.1 | 0.2 | |
| Interest Expense | 0.0 | 2.9 | 2.9 | 0.8 | 0.7 | 0.6 | 0.8 | 1.0 | 1.0 | 1.5 | 1.6 | 1.4 | 1.0 | 1.0 | 0.7 | 0.6 | 0.4 | |
| Other Expense | 554.7 | 577.4 | 89.1 | 39.9 | -0.7 | 120.7 | -0.8 | 3.9 | 6.0 | -0.1 | 0.5 | 0.2 | -1.5 | -1.5 | -1.2 | -0.6 | -0.2 | |
| IBT | 535.0 | 522.7 | 45.4 | 58.3 | -410.4 | -215.7 | -189.7 | -141.1 | -86.7 | -53.5 | -47.4 | -10.5 | 6.6 | 10.1 | 10.9 | 4.8 | -2.6 | |
| Income Tax Expense | 67.5 | 63.8 | 7.2 | 4.5 | -0.3 | 11.9 | 4.8 | 3.3 | 4.0 | 3.1 | 4.3 | 1.6 | 1.3 | 1.1 | 4.2 | 3.1 | 2.6 | |
| Net Income | 466.9 | 458.1 | 37.7 | 100.8 | -410.1 | -227.7 | -194.6 | -144.4 | -74.8 | -26.7 | 11.7 | 8.0 | 5.4 | 5.9 | 3.6 | 0.7 | -6.9 |
| Net Income | TTM | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.0 | 0.0 | 18.6 | 18.6 | 0.0 | 0.0 | 17.8 | 0.0 | 0.1 | 0.1 | ||
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| Other Expense | 261.1 | 261.1 | 16.2 | 16.2 | 28.3 | 28.3 | 13.3 | 13.3 | 30.3 | 30.3 | ||
| IBT | 259.4 | 259.4 | 8.2 | 8.2 | 14.5 | 14.5 | -33.3 | -33.3 | 86.1 | 86.1 | ||
| Income Tax Expense | 31.6 | 31.6 | 2.2 | 2.2 | 1.4 | 1.4 | 0.9 | 0.9 | 1.4 | 1.4 | ||
| Net Income | 227.5 | 227.5 | 6.0 | 6.0 | 12.9 | 12.9 | -33.9 | -33.9 | 84.3 | 84.3 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.59 | $-2.42 | $-1.44 | $-1.39 | $-1.08 | $-0.56 | $-0.22 | $0.10 | $-0.32 | $0.05 | $0.06 | $0.04 | $0.01 | $-0.07 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.58 | $-2.42 | $-1.44 | $-1.39 | $-1.08 | $-0.56 | $-0.22 | $0.10 | $-0.32 | $0.05 | $0.06 | $0.03 | $0.01 | $-0.07 | |
| Shares Outstanding | 175.0 | 171.7 | 171.1 | 169.9 | 169.4 | 158.5 | 139.6 | 133.1 | 132.9 | 123.4 | 119.4 | 109.3 | 105.1 | 104.1 | 103.8 | 103.5 | 103.1 | |
| Diluted Shares Outstanding | 174.5 | 174.6 | 174.6 | 173.8 | 169.4 | 158.5 | 139.6 | 133.1 | 132.9 | 123.4 | 119.9 | 109.3 | 105.8 | 105.8 | 105.3 | 105.3 | 103.1 |
| Per Share Data | TTM | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.04 | $-0.04 | $0.10 | $0.10 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.04 | $-0.04 | $0.10 | $0.10 | ||
| Shares Outstanding | 175.0 | 175.0 | 238.4 | 238.4 | 172.0 | 172.0 | 852.4 | 852.4 | 887.1 | 887.1 | ||
| Diluted Shares Outstanding | 174.5 | 174.5 | 174.6 | 174.6 | 174.5 | 174.5 | 852.4 | 852.4 | 867.0 | 867.0 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 204.0 | 154.0 | 283.6 | 313.3 | 377.5 | 235.6 | 121.2 | 86.0 | 85.3 | 79.4 | 31.9 | 51.1 | 46.9 | 62.0 | 53.8 | 45.3 | |
| Short Term Investments | 599.6 | 682.2 | 602.7 | 317.7 | 634.2 | 199.5 | 96.0 | 214.9 | 273.0 | 24.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.2 | |
| Total Cash & ST Investments | 803.5 | 836.1 | 886.3 | 631.0 | 1,011.7 | 435.2 | 217.2 | 301.0 | 358.3 | 103.7 | 31.9 | 51.1 | 46.9 | 62.0 | 53.8 | 45.3 | |
| Accounts Receivable | 156.9 | 167.7 | 150.5 | 98.0 | 83.6 | 46.6 | 41.4 | 0.0 | 57.2 | 48.9 | 47.9 | 36.0 | 18.8 | 63.3 | 0.0 | 5.1 | |
| Inventory | 46.4 | 50.4 | 50.3 | 56.7 | 35.8 | 19.8 | 16.2 | 12.3 | 11.8 | 12.8 | 9.6 | 4.4 | 1.4 | 25.3 | 28.7 | 26.6 | |
| Other Current Assets | 41.4 | 12.3 | 9.8 | 152.2 | 81.0 | 29.2 | 42.2 | 57.3 | 2.0 | 0.6 | 0.3 | 14.7 | 0.0 | 3.9 | 58.2 | 30.7 | |
| Total Current Assets | 1,048.3 | 1,066.6 | 1,096.8 | 839.9 | 1,212.1 | 530.7 | 317.0 | 370.5 | 432.2 | 167.4 | 89.7 | 94.1 | 67.0 | 150.6 | 140.6 | 107.8 |
| Current Assets | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 1,364.5 | 110.7 | 154.0 | 154.0 | 204.0 | 204.0 | 283.6 | 283.6 | 223.0 | 223.0 | |
| Short Term Investments | 0.0 | 1,254.9 | 682.2 | 684.8 | 599.6 | 599.6 | 602.7 | 605.4 | 633.2 | 635.4 | |
| Total Cash & ST Investments | 1,364.5 | 1,365.6 | 836.1 | 838.8 | 803.5 | 803.5 | 886.3 | 889.0 | 856.2 | 858.4 | |
| Accounts Receivable | 147.0 | 147.0 | 167.7 | 155.5 | 156.9 | 156.9 | 116.9 | 116.9 | 129.2 | 129.2 | |
| Inventory | 0.0 | 48.5 | 50.4 | 50.4 | 46.4 | 46.4 | 50.3 | 50.3 | 53.9 | 53.9 | |
| Other Current Assets | 80.8 | 31.3 | 12.3 | 21.9 | 41.4 | 41.4 | 40.7 | 40.7 | 49.0 | 49.0 | |
| Total Current Assets | 1,592.3 | 1,592.3 | 1,066.6 | 1,066.6 | 1,048.3 | 1,048.3 | 1,096.8 | 1,096.8 | 1,090.5 | 1,090.5 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 94.8 | 97.0 | 104.4 | 84.7 | 66.3 | 45.3 | 27.5 | 17.8 | 15.5 | 11.2 | 9.9 | 8.9 | 6.5 | 33.3 | 29.5 | 29.9 | |
| Goodwill | 0.0 | 0.0 | 3.1 | 0.0 | 3.4 | 3.3 | 3.1 | 3.2 | 3.3 | 3.1 | 3.3 | 2.0 | 0.4 | 8.3 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 167.7 | 0.0 | 0.0 | 0.2 | 0.2 | 0.3 | 0.3 | 0.4 | 0.5 | 0.6 | 0.7 | 0.4 | 15.6 | 23.1 | 18.0 | |
| Long-Term Investments | 80.5 | -599.4 | 48.4 | -243.9 | -557.7 | -60.0 | 2.9 | -76.6 | 144.2 | 158.5 | 119.8 | 113.0 | 111.4 | 0.0 | 0.0 | -1.2 | |
| Other Long-Term Assets | 37.3 | 697.6 | 11.6 | 333.5 | 639.0 | 203.1 | 113.5 | 216.3 | 1.6 | 1.8 | 6.6 | 0.0 | 0.0 | 0.0 | 0.0 | 4.2 | |
| Total Long-Term Assets | 212.6 | 207.6 | 182.9 | 189.6 | 160.6 | 193.4 | 148.1 | 161.6 | 165.7 | 175.1 | 140.1 | 124.8 | 118.6 | 58.9 | 54.1 | 52.2 | |
| Total Assets | 1,260.9 | 1,274.2 | 1,279.8 | 1,029.4 | 1,372.7 | 724.1 | 465.1 | 532.1 | 597.9 | 342.4 | 229.8 | 218.9 | 185.7 | 209.5 | 194.8 | 159.9 |
| Long-Term Assets | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 94.6 | 94.6 | 97.0 | 97.0 | 94.8 | 94.8 | 104.4 | 104.4 | 96.8 | 96.8 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.1 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 167.7 | 0.0 | 0.0 | 0.0 | 599.7 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 8.6 | 8.6 | -599.4 | 82.8 | 80.5 | 80.5 | -554.3 | 48.4 | -595.4 | 37.7 | |
| Other Long-Term Assets | 80.4 | 80.4 | 98.2 | 27.9 | 37.3 | 37.3 | 14.7 | 30.1 | 705.6 | 72.4 | |
| Total Long-Term Assets | 183.6 | 183.6 | 207.6 | 207.6 | 212.6 | 212.6 | 182.9 | 182.9 | 207.0 | 207.0 | |
| Total Assets | 1,775.9 | 1,775.9 | 1,274.2 | 1,274.2 | 1,260.9 | 1,260.9 | 1,279.8 | 1,279.8 | 1,297.5 | 1,297.5 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 43.4 | 42.5 | 36.3 | 71.1 | 41.2 | 31.6 | 24.0 | 25.6 | 24.4 | 35.5 | 24.1 | 29.1 | 11.5 | 18.9 | 16.5 | 10.6 | |
| Short-Term Debt | 26.5 | 26.3 | 35.1 | 264.6 | 26.9 | 2.8 | 3.2 | 0.0 | 30.0 | 20.0 | 23.1 | 26.3 | 51.5 | 11.2 | 30.0 | 24.5 | |
| Other Current Liabilities | 255.3 | 306.2 | 271.4 | 18.2 | 17.2 | 0.4 | 0.4 | 59.9 | 47.7 | 37.8 | 32.7 | 13.2 | 12.3 | 4.1 | 40.9 | 43.1 | |
| Current Liabilities | 373.3 | 376.6 | 403.0 | 353.9 | 311.7 | 158.4 | 113.1 | 85.5 | 104.6 | 95.1 | 81.1 | 69.2 | 78.4 | 81.1 | 88.5 | 67.6 |
| Current Liabilities | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 43.7 | 43.7 | 42.5 | 42.5 | 43.4 | 43.4 | 36.3 | 36.3 | 54.6 | 54.6 | |
| Short-Term Debt | 29.7 | 29.7 | 26.3 | 26.3 | 29.4 | 29.4 | 35.1 | 35.1 | 0.0 | 0.0 | |
| Other Current Liabilities | 269.0 | 268.9 | 306.2 | 307.7 | 297.4 | 300.5 | 271.4 | 331.6 | 286.3 | 286.3 | |
| Current Liabilities | 342.4 | 342.3 | 376.6 | 376.6 | 373.3 | 373.3 | 403.0 | 403.0 | 340.9 | 340.9 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 59.2 | 63.5 | 51.0 | 23.3 | 7.2 | 32.9 | 29.9 | 26.7 | 0.0 | 26.8 | 26.9 | 26.9 | 0.0 | 26.9 | 0.0 | 0.0 | |
| Capital Leases | 6.5 | 7.0 | 6.8 | 5.2 | 7.2 | 8.8 | 6.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | -60.6 | 3.0 | 1.5 | 2.7 | 2.8 | 5.1 | 3.2 | 4.8 | 4.5 | 4.0 | 3.4 | 2.9 | 2.4 | 2.7 | 1.9 | 1.4 | |
| Total Liabilities | 508.9 | 502.3 | 536.4 | 392.6 | 333.1 | 205.2 | 152.2 | 119.9 | 113.0 | 138.4 | 127.5 | 99.1 | 80.8 | 125.8 | 117.4 | 91.1 |
| Long-Term Liabilities | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 96.6 | 71.0 | 63.5 | 63.5 | 59.2 | 59.2 | 51.0 | 51.0 | 40.1 | 40.1 | |
| Capital Leases | 7.3 | 7.3 | 7.0 | 7.0 | 6.5 | 6.5 | 6.8 | 6.8 | 0.0 | 0.0 | |
| Def. Tax Liability | 0.0 | 0.0 | 3.0 | 0.0 | 0.0 | 0.0 | 1.5 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 534.0 | 534.0 | 502.3 | 502.3 | 508.9 | 508.9 | 536.4 | 536.4 | 497.5 | 497.5 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 87.1 | 87.2 | 87.1 | 86.5 | 86.5 | 72.8 | 66.7 | 66.7 | 66.4 | 60.7 | 56.5 | 53.1 | 52.1 | 52.0 | 51.7 | 51.7 | |
| Retained Earnings | -845.1 | -833.2 | -870.9 | -971.5 | -610.3 | -415.6 | -289.7 | -183.0 | -107.1 | -80.4 | -92.0 | -69.2 | -74.4 | -90.0 | -93.8 | -94.7 | |
| Comprehensive Income | -9.5 | -11.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.2 | 5.4 | -4.3 | 5.0 | -12.8 | -12.1 | -33.9 | -32.8 | -34.3 | |
| Total Common Equity | 740.1 | 759.9 | 730.5 | 610.4 | 986.9 | 484.1 | 288.0 | 389.0 | 461.7 | 184.3 | 83.4 | 94.9 | 88.9 | 70.6 | 64.8 | 59.6 |
| Total Common Equity | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 87.2 | 87.2 | 87.2 | 87.2 | 87.1 | 87.1 | 87.1 | 87.1 | 86.6 | 86.6 | |
| Retained Earnings | -380.3 | -380.3 | -833.2 | -833.2 | -845.1 | -845.1 | -870.9 | -870.9 | -803.1 | -803.1 | |
| Comprehensive Income | -5.5 | -5.5 | -11.6 | -11.6 | -9.5 | -9.5 | -8.2 | -8.2 | -7.8 | -7.8 | |
| Total Common Equity | 1,229.1 | 1,229.1 | 759.9 | 759.9 | 740.1 | 740.1 | 730.5 | 730.5 | 782.0 | 782.0 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 85.7 | 89.8 | 86.1 | 23.3 | 34.1 | 35.7 | 33.1 | 26.7 | 30.0 | 46.8 | 50.0 | 53.2 | 51.5 | 38.1 | 30.0 | 24.5 | |
| Book Value | 752.0 | 771.9 | 743.4 | 636.9 | 1,039.5 | 518.9 | 312.9 | 412.3 | 485.0 | 204.1 | 102.3 | 119.9 | 104.8 | 83.6 | 77.3 | 68.8 |
| Other | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 12.9 | 12.9 | 11.9 | 11.9 | 11.9 | 11.9 | 12.8 | 12.8 | 18.0 | 18.0 | |
| Book Value | 1,229.1 | 1,229.1 | 759.9 | 759.9 | 740.1 | 740.1 | 730.5 | 730.5 | 782.0 | 782.0 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -42.0 | 458.1 | 37.7 | 100.8 | -360.4 | -167.0 | -115.5 | -103.7 | -71.3 | -23.0 | 14.6 | 10.4 | 7.3 | 7.0 | 3.5 | 5.4 | -2.2 | |
| Depreciation & Amortization | 10.6 | 13.3 | 12.3 | 8.2 | 8.7 | 7.2 | 6.1 | 4.9 | 3.6 | 2.6 | 2.3 | 2.0 | 1.3 | 1.0 | 4.0 | 4.6 | 4.6 | |
| Stock-Based Compensation | 34.1 | 0.0 | 21.6 | 36.6 | 30.6 | 42.0 | 19.6 | 11.6 | 10.1 | 4.7 | 3.4 | 1.5 | 0.9 | 0.4 | 0.8 | 0.9 | 0.3 | |
| Change Working Capital | 7.5 | -61.0 | -62.2 | 71.1 | 58.7 | 32.5 | 29.3 | 16.1 | 7.0 | -14.3 | 3.2 | -10.2 | 2.4 | -4.4 | 15.5 | -2.5 | -21.0 | |
| Change In Accounts Receivable | -29.9 | 28.9 | -41.6 | -21.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -7.3 | -12.0 | 0.0 | -3.9 | 7.1 | 0.0 | 0.0 | |
| Change In Accounts Payable | -9.6 | 3.0 | 6.2 | -32.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.8 | 3.7 | 2.2 | 1.0 | 2.4 | 0.0 | 0.0 | |
| Change In Inventories | 5.0 | 9.6 | -0.8 | 4.1 | -21.2 | -16.0 | -3.6 | -4.2 | -0.6 | 1.0 | -3.4 | -5.2 | 0.1 | -0.1 | -0.1 | -2.2 | -9.3 | |
| Other Non-cash Items | -57.3 | -475.3 | -9.0 | 105.3 | -6.2 | -3.7 | -2.1 | 0.4 | 0.1 | 0.1 | 0.1 | 2.5 | 0.1 | 0.0 | 0.6 | -3.2 | 0.4 | |
| Cash from Operations | -47.0 | 0.0 | 0.0 | 219.3 | -268.6 | -204.2 | -62.1 | -80.9 | -32.8 | -8.9 | -9.6 | -9.4 | 13.4 | 5.0 | 15.7 | 5.2 | -19.8 |
| Cash Flow From Operating Activities | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 227.5 | 227.5 | 6.0 | 6.0 | 12.9 | 12.9 | -33.9 | -33.9 | 84.3 | 84.3 | |
| Depreciation & Amortization | 3.1 | 3.1 | 3.0 | 3.0 | 3.1 | 3.1 | 2.2 | 2.2 | 1.9 | 1.9 | |
| Stock-Based Compensation | 3.8 | 3.8 | 5.1 | 5.1 | 5.7 | 5.7 | 11.4 | 11.4 | 6.9 | 6.9 | |
| Change Working Capital | -15.7 | -15.7 | -0.6 | -0.6 | -20.6 | -20.6 | 24.4 | 24.4 | -32.4 | -32.4 | |
| Change In Accounts Receivable | 4.3 | 4.3 | 0.7 | 0.7 | -19.9 | -19.9 | 5.0 | 5.0 | -15.7 | -15.7 | |
| Change In Accounts Payable | 0.0 | 0.0 | 0.0 | 0.0 | 7.1 | 0.0 | -16.7 | 0.0 | -16.5 | 0.0 | |
| Change In Inventories | 1.0 | 1.0 | -2.2 | -2.2 | 1.8 | 1.8 | 0.7 | 0.7 | 1.4 | 1.4 | |
| Other Non-cash Items | -255.2 | -255.2 | 6.6 | 6.6 | -21.0 | -21.0 | -7.6 | -7.6 | 52.5 | 52.5 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -3.6 | -3.6 | 113.2 | 113.2 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -18.4 | -24.2 | -17.9 | -32.6 | -36.7 | -16.8 | -19.6 | -8.6 | -6.4 | -5.0 | -4.3 | -3.3 | -3.7 | -2.5 | -12.1 | -6.3 | -8.7 | |
| Acquisitions | -3.1 | 0.0 | 0.0 | -3.0 | 0.3 | 159.1 | 0.0 | 8.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 | 0.4 | -2.7 | |
| Investments | -1,818.9 | -2,749.5 | -1,848.8 | -1,627.9 | -1,202.0 | -1,371.0 | -732.9 | -478.1 | -911.6 | -332.0 | -85.9 | 12.2 | -12.2 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Sales of Investment | 1,877.6 | 2,744.2 | 1,769.4 | 1,372.3 | 1,518.5 | 921.4 | 629.4 | 597.0 | 961.7 | 76.3 | 56.6 | 12.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | |
| Other Investing Activities | 37.7 | 0.0 | 0.0 | 0.0 | 16.5 | 0.9 | -2.3 | 0.0 | 0.0 | 0.0 | 0.0 | -12.2 | -5.0 | 0.0 | 0.1 | 0.1 | 0.2 | |
| Cash from Investing | 19.4 | 0.0 | 0.0 | -291.1 | 296.6 | -306.3 | -125.4 | 119.0 | 43.8 | -260.8 | -33.6 | 8.9 | -20.2 | -2.5 | -12.0 | -5.8 | -11.0 |
| Cash Flow From Investing Activities | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -4.6 | -4.6 | -3.9 | -3.9 | -5.1 | -5.1 | -4.1 | -4.1 | -12.2 | -12.2 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -3.1 | 0.0 | 0.0 | 0.0 | |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 | -991.1 | 0.0 | -827.9 | 0.0 | -835.1 | 0.0 | |
| Sales of Investment | 0.0 | 0.0 | 0.0 | 0.0 | 995.3 | 0.0 | 882.3 | 0.0 | 519.6 | 0.0 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 16.5 | 16.5 | -145.8 | -145.8 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 12.4 | 12.4 | -158.0 | -158.0 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -44.4 | 0.0 | 0.0 | 61.7 | -26.9 | -99.7 | 0.0 | -26.9 | -30.0 | -49.5 | -28.2 | -6.4 | -11.3 | -0.6 | -18.8 | -0.9 | -8.3 | |
| Debt Issued | 175.7 | 89.8 | 3.7 | 124.5 | 16.2 | 98.1 | 2.6 | 33.3 | 26.8 | 32.7 | 25.0 | 3.2 | 13.0 | 14.0 | 26.9 | 6.5 | 32.8 | |
| Issuance of Common Stock | 4.4 | 0.0 | 0.0 | 5.1 | 0.2 | 717.3 | 318.9 | 0.3 | 3.9 | 301.7 | 110.6 | 1.4 | 2.8 | 0.0 | 0.6 | 0.0 | 0.8 | |
| Repurchase of Common Stock | -36.3 | 0.0 | -36.1 | -9.1 | -48.1 | -27.3 | -12.9 | -0.3 | -5.5 | -1.4 | -0.6 | -1.8 | 0.0 | 0.0 | -6.5 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | -87.4 | -99.7 | 0.0 | 0.0 | -24.9 | 0.0 | -11.7 | -2.6 | 0.0 | 0.0 | -0.5 | 0.0 | 0.0 | |
| Other Financing Activities | 46.3 | 0.0 | 0.0 | -9.1 | 79.5 | 159.5 | -9.6 | 25.5 | 48.3 | 22.4 | 22.3 | 3.9 | 7.8 | 13.7 | 29.4 | 8.8 | 41.4 | |
| Cash from Financing | 10.3 | 0.0 | 0.0 | 48.7 | -82.8 | 650.0 | 296.4 | -1.5 | -8.2 | 273.2 | 92.4 | -5.5 | -0.6 | 13.1 | 4.2 | 7.9 | 34.0 |
| Cash Flow From Financing Activities | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | -7.3 | 10.9 | 89.8 | 1.2 | 88.6 | 2.5 | 3.9 | 42.1 | 40.1 | 16.8 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 4.1 | 0.0 | 0.0 | 0.0 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | -18.0 | -18.0 | -0.2 | 0.0 | -4.5 | -4.5 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 21.4 | 21.4 | 7.5 | 7.5 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 21.4 | 21.4 | 2.9 | 2.9 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -251.6 | -82.6 | -129.6 | -29.7 | -64.3 | 141.9 | 114.5 | 35.1 | 0.8 | 5.8 | 47.5 | -7.0 | -7.9 | 16.1 | 8.2 | 8.5 | 3.6 | |
| Closing Cash Balance | 204.0 | 71.3 | 154.0 | 283.6 | 313.3 | 377.5 | 235.6 | 121.2 | 86.0 | 85.3 | 79.4 | 31.9 | 38.9 | 46.9 | 62.0 | 23.7 | 20.8 |
| Cash position | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 0.0 | 0.0 | 0.0 | -204.0 | 204.0 | -39.8 | 60.6 | -192.7 | -90.3 | -45.1 | |
| Closing Cash Balance | 0.0 | 0.0 | 0.0 | 0.0 | 204.0 | -39.8 | 283.6 | 30.3 | 223.0 | -45.1 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -65.3 | -79.0 | -17.4 | 186.6 | -305.3 | -221.0 | -81.6 | -89.5 | -39.2 | -14.0 | -13.9 | -12.7 | 9.6 | 2.5 | 3.6 | -1.1 | -28.5 | |
| Real Free Cash Flow | -99.5 | -79.0 | -39.0 | 150.0 | -335.8 | -263.0 | -101.3 | -101.1 | -49.3 | -18.7 | -17.3 | -14.2 | 8.8 | 2.2 | 2.8 | -2.0 | -28.8 |
| Free Cash Flow | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -41.1 | -41.1 | 16.3 | 16.3 | -25.0 | -25.0 | -7.7 | -7.7 | 101.0 | 101.0 | |
| Real Free Cash Flow | -44.9 | -44.9 | 11.1 | 11.1 | -30.6 | -30.6 | -19.1 | -19.1 | 94.1 | 94.1 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 5.2 | 14.1 | 2356.8 |
| P/S | 4 | 20.2 | 70.5 |
| P/B | 2 | 11.1 | 2015.4 |
| P/FCF | -36 | -102.3 | 7573.5 |
| Market cap | $2.6 | $5.0 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 5.3 % | 7.7 % | 0 % |
| Debt to Income | 20 % | -218.3 % | 0 % |
| Debt to Free cash flow | -138.1 % | -4.3 % | 0 % |
| Interest expense percentage | 0 % | 83 % | 0 % |
| Current ratio | 4.7 | 2.4 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 38 % | -7.8 % | 0 % |
| ROA | 26.3 % | -5.4 % | 0 % |
| CapEx to Revenue | 2.8 % | 2.5 % | 0 % |
| RaD to Revenue | 0 % | 12.7 % | 0 % |
| ROEM | 332,521.8 | 43334.5 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 8.9 % | 14.1 % | 67.7 % |
| Operating margin | -3.3 % | -29.3 % | -263.4 % |
| Net margin | 77.5 % | -28.6 % | -255.6 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0.4 % | 0 % |
| Dividend payout percentage | 0 % | -5.1 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 174.5 mil | 153.5 mil |
| Employee count | 1.8 tis | 1.4 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
